The interplay between innate and adaptive immunity regulates cancer development

Cancer Immunology, Immunotherapy

Volumn 54, Issue 11, 2005, Pages 1143-1152

  De Visser, K E ^a   Coussens, L M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adaptive immune system; Antibody; Cancer; Inflammation; Innate immune system; Premalignant

Indexed keywords

ANTIINFLAMMATORY AGENT; B LYMPHOCYTE ANTIBODY; CD20 ANTIBODY; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; T LYMPHOCYTE ANTIBODY;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMPLEMENT SYSTEM; CONFERENCE PAPER; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; CHRONIC DISEASE; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; LYMPHOCYTES; NEOPLASMS;

EID: 25844490025     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0702-5     Document Type: Conference Paper

References (104)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57
2. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860
3. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382
4. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481
5. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285
6. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289
7. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461
8. Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409
9. Gorman C, Leandro M, Isenberg D (2003) B cell depletion in autoimmune disease. Arthritis Res Ther 5 (Suppl 4):S17
10. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D (2002) Arthritis critically dependent on innate immune system players. Immunity 16:157
11. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451
12. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480
13. Matsumoto I, Staub A, Benoist C, Mathis D (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732
14. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114:679
15. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499
16. Sahu A, Lambris JD (2001) Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35
17. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058
18. Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344:1140
19. Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23:201
20. Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981
21. Goldrath AW, Bevan MJ (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402:255
22. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575
23. McHeyzer-Williams MG (2003) B cells as effectors. Curr Opin Immunol 15:354
24. Janeway CA, Travers P, Walport M, Shlomchik M (2001) Immunobiology. Garland, New York
25. Sprent J, Surh CD (2002) T cell memory. Annu Rev Immunol 20:551
26. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11
27. Granucci F, Zanoni I, Feau S, Ricciardi-Castagnoli P (2003) Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. Embo J 22:2546
28. Ottenhoff TH, Kumararatne D, Casanova JL (1998) Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 19:491
29. Mempel TR, Henrickson SE, Von Andrian UH (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154
30. Foti M, Granucci F, Ricciardi-Castagnoli P (2004) A central role for tissue-resident dendritic cells in innate responses. Trends Immunol 25:650
31. Kroczek RA, Mages HW, Hutloff A (2004) Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 16:321
32. Alahlafi AM, Wordsworth P, Wojnarowska F (2004) The lupus band: do the autoantibodies target collagen VII? Br J Dermatol 150:504
33. Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM (2004) Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol 172:7694
34. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C (2000) A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406:998
35. Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA (1995) The role of complement in experimental bullous pemphigoid. J Clin Invest 95:1539
36. Hogarth PM (2002) Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 14:798
37. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275
38. Sylvestre DL, Ravetch JV (1996) A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 5:387
39. Watanabe N, Akikusa B, Park SY, Ohno H, Fossati L, Vecchietti G, Gessner JE, Schmidt RE, Verbeek JS, Ryffel B, Iwamoto I, Izui S, Saito T (1999) Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fcgamma receptors. Blood 94:3855
40. Clynes R, Dumitru C, Ravetch JV (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052
41. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572
42. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952
43. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511
44. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580
45. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE (2003) Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 10:309
46. Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H (2003) Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 89:1736
47. Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S, Katoh H (2003) Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 84:224
48. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M (2003) CD4(+) T cells in cancer stroma, not CD8(+) T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94:1003
49. Benitez-Bribiesca L, Wong A, Utrera D, Castellanos E (2001) The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 49:1061
50. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254
51. Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15:1087
52. Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158
53. Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686
54. Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology 16:217
55. Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118:671
56. Turini ME, DuBois RN (2002) Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35
57. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539
58. Arbeit JM, Munger K, Howley PM, Hanahan D (1994) Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68:4358
59. Coussens LM, Hanahan D, Arbeit JM (1996) Genetic pre-disposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Path 149:1899
60. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727
61. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447
62. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678
63. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53:64
64. Kusmartsev S, Gabrilovich DI (2002) Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51:293
65. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398
66. Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431:405
67. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62:7042
68. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57:630
69. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737
70. de Visser KE, Coussens LM (2004) Inflammation and matrix metalloproteinases: implications for cancer development. In: Morgan DW, Forssmann UJ, Nakada MT (eds) Cancer and inflammation. Birkhauser, Basel, p 71
71. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161
72. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, Coussens LM (2002) Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 70:501
73. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137
74. Pardoll DM (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807
75. Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2:373
76. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L et al (1995) Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 60:183
77. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681
78. Penn I (1999) Posttransplant malignancies. Transplant Proc 31:1260
79. Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I, Hardesty RL, Hattler BG, Griffith BP (1995) Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 60:1623
80. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B (2001) De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 7:S109
81. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ (2001) Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 154:544
82. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G (1995) Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346:796
83. Alaedini A, Green PH (2005) Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 142:289
84. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500
85. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y (1994) Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 3:59
86. Artinian V, Kvale PA (2004) Cancer and interstitial lung disease. Curr Opin Pulm Med 10:425
87. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753
88. Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497
89. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ (2003) National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 30:958
90. Cibere J, Sibley J, Haga M (1997) Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580
91. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307
92. Agassy-Cahalon L, Yaakubowicz M, Witz IP, Smorodinsky NI (1988) The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. Immunol Lett 18:181
93. Kaliss N (1958) Immunological enhancement of tumor homografts in mice: a review. Cancer Res 18:992
94. Snell GD (1957) Incompatibility reactions to tumor homotransplants with particular reference to the role of the tumor; a review. Cancer Res 17:2
95. Brodt P, Gordon J (1982) Natural resistance mechanisms may play a role in protection against chemical carcinogenesis. Cancer Immunol Immunother 13:125
96. Monach PA, Schreiber H, Rowley DA (1993) CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55:1356
97. Schreiber H, Wu TH, Nachman J, Rowley DA (2000) Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol 10:351
98. Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H (2000) Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 191:1945
99. Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB (1999) Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1:453
100. de Visser KE, Korets LV, Coussens LM (2004) Early neoplastic progression is complement independent. Neoplasia 6:768
101. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Huntingt) 12:1763
102. Bussel JB (2000) Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37:261
103. von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343
104. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte-dependent. Cancer Cell in press